Semaglutide
Enhanced albumin binding is the modification that extends the action of semaglutide, an analogue of the gut hormone GLP-1 with an elimination half-life of about seven days. Agonism at the GLP-1 receptor stimulates glucose-dependent insulin release, suppresses appetite and slows gastric emptying, producing improved glycaemic control together with substantial weight reduction. Cardiovascular outcome data extend the picture: in people with established heart disease the agent reduces the rate of serious events such as myocardial infarction and stroke. Both injectable and oral presentations exist, unusual for a peptide of this size. It is a protein of formula C187H291N45O59, roughly 4114 g/mol, within the alimentary tract and metabolism group.
Mimicking a natural gut hormone called GLP-1, this injectable or oral medication stimulates insulin release, reduces appetite, and slows stomach emptying, leading to better blood sugar control and meaningful weight loss. It has also been shown to reduce the risk of serious cardiovascular events such as heart attack and stroke in people with established heart disease.
分子量
4114.0000 g/mol
LogP
-5.80
TPSA
1650.00 Ų
Lipinski 五规则
不符合
治疗领域
药物分类
作用机制
GLP-1 receptor agonist with enhanced albumin binding for extended action.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
GLP-1 receptor agonist with enhanced albumin binding for extended action.
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
InChI
InChI=1S/C187H291N45O59/c1-18-105(10)154(180(282)208-108(13)159(261)216-133(86-114-89-200-119-50-40-39-49-117(114)119)170(272)218-129(82-102(4)5)171(273)228-152(103(6)7)178(280)215-121(53-44-72-199-186(192)193)162(264)201-91-141(242)209-120(52-43-71-198-185(190)191)161(263)204-94-151(257)258)230-172(274)131(83-111-45-33-31-34-46-111)219-167(269)126(64-69-149(253)254)214-166(268)122(51-41-42-70-195-144(245)98-290-79-78-289-76-74-197-145(246)99-291-80-77-288-75-73-196-139(240)66-61-127(183(285)286)211-140(241)54-37-29-27-25-23-21-19-20-22-24-26-28-30-38-55-146(247)248)212-158(260)107(12)206-157(259)106(11)207-165(267)125(60-65-138(189)239)210-142(243)92-202-163(265)123(62-67-147(249)250)213-168(270)128(81-101(2)3)217-169(271)130(85-113-56-58-116(238)59-57-113)220-175(277)135(95-233)223-177(279)137(97-235)224-179(281)153(104(8)9)229-174(276)134(88-150(255)256)221-176(278)136(96-234)225-182(284)156(110(15)237)231-173(275)132(84-112-47-35-32-36-48-112)222-181(283)155(109(14)236)227-143(244)93-203-164(266)124(63-68-148(251)252)226-184(287)187(16,17)232-160(262)118(188)87-115-90-194-100-205-115/h31-36,39-40,45-50,56-59,89-90,100-110,118,120-137,152-156,200,233-238H,18-30,37-38,41-44,51-55,60-88,91-99,188H2,1-17H3,(H2,189,239)(H,194,205)(H,195,245)(H,196,240)(H,197,246)(H,201,264)(H,202,265)(H,203,266)(H,204,263)(H,206,259)(H,207,267)(H,208,282)(H,209,242)(H,210,243)(H,211,241)(H,212,260)(H,213,270)(H,214,268)(H,215,280)(H,216,261)(H,217,271)(H,218,272)(H,219,269)(H,220,277)(H,221,278)(H,222,283)(H,223,279)(H,224,281)(H,225,284)(H,226,287)(H,227,244)(H,228,273)(H,229,276)(H,230,274)(H,231,275)(H,232,262)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H,285,286)(H4,190,191,198)(H4,192,193,199)/t105-,106-,107-,108-,109+,110+,118-,120-,121-,122-,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,152-,153-,154-,155-,156-/m0/s1
Molecular Formula
C187H291N45O59
HBD / HBA
57 / 63
可旋转键数
151
重原子数
291
No targets recorded
Target interaction data is not yet available for this drug.
Semaglutide slows gastric emptying, potentially reducing and delaying oral warfarin absorption, leading to variable changes in INR that complicate anticoagulation management.
Combining semaglutide with insulin glargine increases hypoglycaemia risk; however, the combination is used clinically with appropriate dose adjustments for improved glycaemic control.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Mimicking a natural gut hormone called GLP-1, this injectable or oral medication stimulates insulin release, reduces appetite, and slows stomach emptying, leading to better blood sugar control and meaningful weight loss. It has also been shown to reduce the risk of serious cardiovascular events such as heart attack and stroke in people with established heart disease.
GLP-1 receptor agonist with enhanced albumin binding for extended action.
Key pharmacokinetic parameters for Semaglutide: Half-life: 7 days.
Yes, Semaglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108724. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 56843331. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="semaglutide"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/semaglutide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/semaglutide/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/semaglutide/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="semaglutide"></drugfyi-drug>